Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital Olomouc | OTHER |
Not provided
Not provided
Not provided
Not provided
Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.
Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like Cystic fibrosis (CF) or Bronchial asthma (AB) would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Asthma | Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment. |
| |
| Cystic fibrosis | Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration. |
| |
| Healthy control | Healthy control children/adults without chronic or autoimmune disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Collection of breath condensate | Diagnostic Test | Breath condensate will be collected from the patients involved in study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine | Biomarker iidentification in EBC using method of High Resolution Mass Spectrometry in patients with bronchial astma, cystic fibrosis and healthy control. | 18 months from the screening |
| FEV1 determination in Cystic Fibrosis patients | Spirometry - FEV1 in Cystic Fibrosis patients and its correlation with biomarker results. | 18 months from the screening |
| FVC determination in Cystic Fibrosis patients | Spirometry - FVC in Cystic Fibrosis patients and its correlation with biomarker results. | 18 months from the screening |
| Amylase readings in blood serum in Cystic Fibrosis patients | Amylase readings in blood serum in Cystic Fibrosis patients and its correlation with biomarker results. | 18 months from the screening |
| Lipase readings in blood serum in Cystic Fibrosis patients | Lipase readings in blood serum in Cystic Fibrosis patients and its correlation with biomarker results. | 18 months from the screening |
| Microbiology cultivation in Cystic Fibrosis patients | Sampling for microbiology cultivation and determination of microbes present in EBC, correlation with biomarker results. | 18 months from the screening |
| CT in Cystic Fibrosis patients |
| Measure | Description | Time Frame |
|---|---|---|
| Inflamatory biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine | Inflamatory biomarker identification in EBC using method of High Resolution Mass Spectrometry in patients with bronchial astma, cystic fibrosis and healthy control. | 18 months from the screening |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Petr Dzubak, MD, PhD. | Contact | 585632150 | +420 | petr.dzubak@upol.cz |
| Marian Hajduch, MD, PhD | Contact | 585632 | +420 | marian.hajduch@upol.cz |
| Name | Affiliation | Role |
|---|---|---|
| Petr Dzubak, MD, PhD. | The Institute of Molecular and Translational Medicine, Czech Republic | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Olomouc | Recruiting | Olomouc | 77900 | Czechia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Breath condensate, serum and blood plasma
CT imaging of Cystic Fibrosis patients, correlation with biomarker results. |
| 18 months from the screening |
| RTG in Cystic Fibrosis patients | RTG imaging of Cystic Fibrosis patients, correlation with biomarker results. | 18 months from the screening |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |